FindTrial
Sign In

Post-marketing clinical study of OIF in chronic myeloid leukemia (CML)

Post-marketing clinical study of OIF in chronic myeloid leukemia (CML)

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220037
Enrollment
Unknown
Registered
2005-09-06
Start date
2005-09-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CML

Interventions

investigational material(s) Generic name etc : Interferon alpha-nl INN of investigational material : Therapeutic category code : 639 Other biological preparations Dosage and Administration for Invest

Sponsors

Otsuka Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with CML, aged between 15 and 74 years, inclusive, at time of consent

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy/safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026